Study S000635

A Multicenter, Randomized, Controlled Clinical Study of 3mg Once Every Two Weeks Administration of Efsubaglutide Alfa Injection in Type 2 Diabetes Patients With Poor Glycemic Control After Diet and Exercise Intervention.

ClinicalTrials.gov record

Registration

Registration: NCT06849843
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: NONE
Status: COMPLETED
Enrollment: 59
Start: 2024-12-18
Primary completion: 2025-05-29
Lead sponsor: Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Conditions: Type2 Diabetes
Interventions: DRUG:Efsubaglutide Alfa Injection
Results posted: FALSE

Registered primary outcomes

HbA1c [12 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.